Fortress Biotech, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Fortress Biotech, Inc. (FBIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 18.90 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-03-31
- Fortress Biotech, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2023-12-31 was 8.00K shares.
- Fortress Biotech, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2023-09-30 was -228.67K shares, a 515.76% decline year-over-year.
- Fortress Biotech, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2023-06-30 was 200.00K shares, a 233.33% increase year-over-year.
- Fortress Biotech, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2023-03-31 was 45.00K shares, a 82.35% decline year-over-year.
- Fortress Biotech, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 18.90K shares.
- Fortress Biotech, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 24.33K shares, a 93.42% decline from fiscal 2022.
- Fortress Biotech, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 370.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2025-12-31 | 18.90K shares 10-K · filed 2026-03-31 | |||
| 2023-12-31 | 8.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -220.67K shares derived: sum of 2 quarters · filed 2024-03-28 | -20.67K shares derived: sum of 3 quarters · filed 2024-03-28 | 24.33K shares 10-K · filed 2024-03-28 |
| 2023-09-30 | -228.67K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -28.67K shares derived: sum of 2 quarters · filed 2023-11-14 | 16.33K shares 10-Q · filed 2023-11-14 | 16.33K shares derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | 200.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 245.00K shares 10-Q · filed 2023-08-14 | 245.00K shares derived: sum of 3 quarters · filed 2023-08-14 | 300.00K shares derived: sum of 4 quarters · filed 2023-08-14 |
| 2023-03-31 | 45.00K shares 10-Q · filed 2023-05-15 | 45.00K shares derived: sum of 2 quarters · filed 2023-05-15 | 100.00K shares derived: sum of 3 quarters · filed 2023-05-15 | 160.00K shares derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | 55.00K shares derived: sum of 2 quarters · filed 2023-03-31 | 115.00K shares derived: sum of 3 quarters · filed 2023-03-31 | 370.00K shares 10-K · filed 2023-03-31 |
| 2022-09-30 | 55.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 115.00K shares derived: sum of 2 quarters · filed 2022-11-14 | 370.00K shares 10-Q · filed 2022-11-14 | |
| 2022-06-30 | 60.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 315.00K shares 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | 255.00K shares 10-Q · filed 2022-05-12 | |||
| 2012-09-30 | 25.00K shares 10-Q · filed 2012-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |